AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer ? Commercialization of Research; and the Université de Montréal. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10
Phone847-932-7900
Debt
Debt-to-Equity Ratio8.70
Current Ratio1.20
Quick Ratio1.10
Price-To-Earnings
Trailing P/E Ratio14.39
Forward P/E Ratio11.40
P/E Growth0.83
Sales & Book Value
Annual Sales$28.22 billion
Price / Sales5.00
Cash Flow$6.5859 per share
Price / Cash13.50
Book Value$3.19 per share
Price / Book27.87
Profitability
EPS (Most Recent Fiscal Year)$5.60
Net Income$5.31 billion
Net Margins21.55%
Return on Equity186.47%
Return on Assets14.42%
Miscellaneous
Employees29,000
Outstanding Shares1,586,880,000
Market Cap$141,089.50
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie announced a quarterly dividend on Thursday, June 14th. Investors of record on Friday, July 13th will be paid a dividend of $0.96 per share on Wednesday, August 15th. This represents a $3.84 annualized dividend and a yield of 4.32%. The ex-dividend date of this dividend is Thursday, July 12th. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its board has approved a share repurchase plan on Friday, February 16th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's leadership believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc (NYSE:ABBV) released its quarterly earnings results on Thursday, April, 26th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.79 by $0.08. The business earned $7.93 billion during the quarter, compared to analysts' expectations of $7.60 billion. AbbVie had a return on equity of 186.47% and a net margin of 21.55%. The company's revenue was up 21.4% on a year-over-year basis. During the same period last year, the company earned $1.28 EPS. View AbbVie's Earnings History.
When is AbbVie's next earnings date?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $7.66-7.76 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.53.
What price target have analysts set for ABBV?
17 Wall Street analysts have issued 12-month price targets for AbbVie's stock. Their predictions range from $65.61 to $157.00. On average, they expect AbbVie's stock price to reach $103.3435 in the next year. This suggests a possible upside of 16.2% from the stock's current price. View Analyst Ratings for AbbVie.
What is the consensus analysts' recommendation for AbbVie?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug, Humira is performing well on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret’s launch has also been stronger than expected. Mavyret has become a major growth driver for AbbVie in a short time on the market. Moreover, AbbVie has a strong late-stage pipeline with label expansions for new and existing products expected over the next few years. Several pivotal data readouts and regulatory milestones are expected in 2018. AbbVie’s shares have slightly outperformed the industry this year. However, Viekira’s sales continue to be hurt by intensifying competition. Also, potential long-term competition to Humira is a concern. Estimates have remained stable ahead of Q2 earnings. AbbVie has a positive record of earnings surprises in the recent quarters." (7/14/2018)
- 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)
Are investors shorting AbbVie?
AbbVie saw a decline in short interest in June. As of June 15th, there was short interest totalling 38,435,690 shares, a decline of 11.6% from the May 31st total of 43,501,770 shares. Based on an average daily volume of 8,827,213 shares, the days-to-cover ratio is presently 4.4 days. Currently, 2.4% of the company's stock are short sold. View AbbVie's Current Options Chain.
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Mr. Richard A. Gonzalez, Chairman & CEO (Age 64)
- Mr. William J. Chase, Exec. VP & CFO (Age 50)
- Mr. Michael E. Severino, Exec. VP of R&D and Chief Scientific Officer (Age 52)
- Ms. Laura J. Schumacher, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. Carlos Alban, Exec. VP of Commercial Operations (Age 55)
Has AbbVie been receiving favorable news coverage?
Media coverage about ABBV stock has trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AbbVie earned a coverage optimism score of 0.14 on Accern's scale. They also gave press coverage about the company an impact score of 45.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are AbbVie's major shareholders?
AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Swedbank (0.09%), NN Investment Partners Holdings N.V. (0.08%), Cornerstone Wealth Management LLC (0.07%), Gateway Investment Advisers LLC (0.05%), Fisher Asset Management LLC (0.05%) and Retirement Systems of Alabama (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Which major investors are selling AbbVie stock?
ABBV stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Retirement Systems of Alabama, Boston Advisors LLC, Calamos Advisors LLC, Assenagon Asset Management S.A., ADAMCAPITAL Gestao de Recursos Ltda., Rhenman & Partners Asset Management AB and Hartford Investment Management Co.. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Which major investors are buying AbbVie stock?
ABBV stock was acquired by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, KAMES CAPITAL plc, Nippon Life Global Investors Americas Inc., Broadleaf Partners LLC, Channing Capital Management LLC, Nikko Asset Management Americas Inc., Whittier Trust Co. and State of Alaska Department of Revenue. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.
How do I buy shares of AbbVie?
Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of ABBV stock can currently be purchased for approximately $88.91.
How big of a company is AbbVie?
AbbVie has a market capitalization of $141.09 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.
How can I contact AbbVie?
AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.
MarketBeat Community Rating for AbbVie (NYSE ABBV)
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
